Background {#Sec1}
==========

Internet-based interventions are seen as an important potential strategy to improve accessibility to high quality treatments in mental healthcare. Especially for depression the need for greater access to cost-effective treatments is stressed out, given the increasing social and economic burden of this disorder \[[@CR1]\]. Depression is highly prevalent and has a severe negative impact on wellbeing, quality of life and social and work-related functioning \[[@CR2]\]. The World Health Organisation (WHO) has predicted that depression will be the foremost overall cause of disability in developed countries by 2030 \[[@CR3]\]. Despite the presence of several efficacious psychological and pharmacological treatments, many depressed individuals remain untreated \[[@CR4]\]. It is estimated that in the Netherlands 40 % of depressed individuals do not receive or seek adequate care \[[@CR5]\]. Deployment of more internet-based interventions may help bridge this gap.

A growing number of studies have demonstrated the clinical efficacy and the potential cost-effectiveness of internet-based treatment for mood disorders in controlled research settings \[[@CR6]--[@CR9]\]. Furthermore, internet-based treatment with professional guidance has found to be more effective than unguided delivery \[[@CR10], [@CR11]\]. A recent meta-analysis even showed, based on a yet limited number of studies, that guided internet-delivered cognitive behavioural therapy (iCBT) results in similar overall effects as regular face-to-face treatment \[[@CR12]\].

Only a few studies have directly compared Internet interventions with face-to-face interventions for depression. In an experimental setting, Wagner et al. \[[@CR13]\] compared similar treatment modules based on cognitive behavioural therapy (CBT) in a guided online format with a regular face-to-face format. Another randomised controlled trial (RCT) compared group-based face-to-face CBT to guided iCBT \[[@CR14]\]. In both non-inferiority studies no significant differences between the treatment modalities were found on treatment outcome, indicating that guided iCBT might be at least as effective as comparable face-to-face delivered interventions.

Most of the above mentioned evidence comes from efficacy trials conducted in controlled research settings. Whether these promising results can be transferred to routine clinical practice is less well known. Patient populations in routine practice are often more heterogeneous in terms of their characteristics, preferences and comorbidity levels than the populations and services in controlled research samples. In a review of Andersson and Hedman (2013), no RCT and only two uncontrolled open studies examining the effectiveness on guided iCBT for depression in routine practice were identified \[[@CR15], [@CR16]\], with medium-large within group effect sizes. Although available evidence suggests that iCBT may be as effective in routine practice as it is in randomised controlled clinical trials \[[@CR17]--[@CR20]\], there clearly is a need for more effectiveness studies on guided iCBT for depression in routine care. Moreover, most studies so far were conducted among self-referred depressed individuals from the general population or in primary care. It is not yet clear whether guided iCBT is a suitable intervention for the more complex patients that are treated in routine specialised mental healthcare settings.

The question is whether the format of guided iCBT should be adapted for the application in routine specialised mental health care. In former studies, therapist support in guided iCBT was usually delivered through e-mail, chat, telephone or video conference \[[@CR21]\]. From a clinical perspective it seems rational that patients with more severe and more complex symptomatology of depression as present in routine care, may need face-to-face interaction \[[@CR22]\]. Therefore, a so called 'blended' treatment might be more appropriate for these settings, where online and face-to-face sessions are integrated into one treatment protocol \[[@CR23]--[@CR25]\]. The face-to-face part of this treatment ensures that the patient benefits from a supportive therapeutic relationship and more social control, that is likely to increase motivation to adhere to and complete treatment \[[@CR26]\]. Therapists can help tailor online treatment by meeting specific individual patient's needs and wishes, have the opportunity to probe more deeply and to give immediate responses. Face-to-face interaction also involves non-verbal cues, which can be crucial in the communication between patient and therapist. The online part of blended treatment means that patients have 24/7 access to treatment modules, offering more flexibility. In addition, mobile applications can support the therapy by real-time monitoring of patient's state ("ecological momentary assessment") and by personalised feedback based on user data ("ecological momentary intervention") \[[@CR27]--[@CR29]\]. Blending online and mobile components with face-to-face therapy could improve patients' active participation in the treatment, increasing self-reliance and self-management competencies, which subsequently may contribute to better long term results \[[@CR13]\]. By extending the reach of the therapy into the daily life of patients, the number of face-to-face sessions required could be reduced, resulting in a decrease of costs. Additionally, waiting times caused by limited availability of clinicians could be reduced when part of the face-to-face sessions are replaced by online treatment, which means therapists can treat more patients in a given time period. Also, other challenges patients meet when seeking traditional care can be tackled with online treatment, such as inconvenience of session times, travel time and -costs or mobility issues \[[@CR30], [@CR31]\].

Until now, only a few studies have investigated blended treatment formats \[[@CR32]--[@CR34]\]. Preliminary findings are promising, indicating that blended treatment can be effective in the reduction of depressive symptoms. However, to date, no data are available on the effectiveness of blended depression treatment compared to traditional face-to-face therapy in routine specialised mental healthcare. To investigate whether blended treatment for depression in routine (specialised) mental health care may be an attractive solution to overcome the aforementioned challenges, the European Commission has granted a large European study (the E-COMPARED project: 'European Comparative Effectiveness Research on Internet-Based Depression Treatment'), in which eight European countries will conduct a similar RCT to assess the clinical and cost-effectiveness of blended treatment for depression compared to treatment as usual (TAU) \[[@CR35]\]. The proposed study is part of the E-COMPARED project and focusses on the RCT in the Netherlands.

Trial objectives {#Sec2}
----------------

The overall objective of E-COMPARED is to provide mental health care stakeholders including policymakers, patients, health care professionals, health insurers and mental health service providers with evidence-based information and recommendations about the (cost-)effectiveness of blended treatment for depression. Within E-COMPARED data will be pooled across eight participating countries, with a total of 1200 participants. This large clinic based sample generates statistical power to analyse treatment impact in terms of depression outcomes and cost-effectiveness as well as in terms of moderators and mediators of outcome, thereby investigating what treatment works best for whom \[[@CR35], [@CR36]\].

This protocol describes the RCT in the Netherlands. The primary objective is to evaluate the clinical and cost-effectiveness of blended Cognitive Behavioural Therapy (bCBT) for adults with a diagnosis of Major Depressive Disorder (MDD), as compared to treatment as usual (TAU). We expect the blended treatment to be at least as effective as the regular treatment for depression in routine specialised mental healthcare (non-inferior), but that the blended form can be offered at lower costs than TAU. Furthermore, the study aims to explore which patients are likely to benefit from this particular kind of treatment delivery and how to tailor blended depression treatment to individual patients, related to their characteristics.

Methods and design {#Sec3}
==================

Study design {#Sec4}
------------

This study is a two-arm parallel non-inferiority randomised controlled trial, comparing internet-based bCBT to routine care that patients receive when treated for MDD in outpatient specialised mental healthcare (TAU). The protocol for this study has been approved by the Medical Ethics Committee of the VU University Medical Centre (registration number 2015.078).

Inclusion and exclusion criteria {#Sec5}
--------------------------------

In order to be eligible, participants must be ≥ 18 years old, have a primary diagnosis of Major Depressive Disorder according to DSM-IV criteria as confirmed with the MINI International Neuropsychiatric Interview (M.I.N.I) \[[@CR37]\], and have a score above 5 on the Patient Health Questionnaire (PHQ-9) \[[@CR38]\]. Participants will be excluded if meeting any of the following criteria: 1) having acute risk of suicide, assessed clinically by trained interviewers with the M.I.N.I.; 2) having serious psychiatric co-morbidity (e.g. bipolar disorder, psychotic illness or substance dependence) that requires alternative treatment, primary to the treatment of MDD; 3) participating in other psychological treatment for depression, parallel to the intervention treatment of the study; 4) insufficient comprehension of the spoken and written Dutch language; 5) not having access to a computer or tablet with internet; 6) not willing to carry an Android smartphone during the treatment period (made available by the research team when they do not have an Android smartphone themselves); 6) not willing to be randomly assigned to one of the two treatment groups, bCBT or TAU.

For applicants that are at high risk for suicide, relevant information and telephone numbers are provided and therapists are notified such that standardised procedures within the participating mental healthcare centres can be followed. When stabilised, the patient can still potentially be eligible to participate.

Recruitment {#Sec6}
-----------

Participants will be recruited within participating specialised mental healthcare centres in the Netherlands. For specialist mental healthcare, patients need a referral from a general practitioner or primary mental healthcare professional. Referred patients first undergo an intake interview by mental healthcare specialists, who determine the diagnosis and treatment plan. During the intake procedure, clinicians will ask all new patients with a primary diagnosis of MDD if they are interested to participate in the study, and provide them with a letter containing detailed information about the study and an informed consent form. Patients who have agreed to be approached by the researchers, will be contacted within a week by telephone and after going through the study information asked whether they are willing to participate. If affirmative, the researcher first screens whether some major study requirements are fulfilled (sufficient command of the Dutch language; no other parallel psychotherapeutic treatment for depression; having access to the internet; willing to carry an Android smartphone during the treatment period; and willing to be allocated randomly to the treatment condition) and the patient will be asked to sign the informed consent form and return it by post. If the initial criteria are fulfilled, the M.I.N.I. diagnostic interview will be conducted by a trained interviewer by telephone to determine depression status and co-morbidity. When eligible, and after receiving the signed informed consent, the researcher sends an e-mail to the patient containing an invitation with a link to fill out the online questionnaires. After completion of the baseline assessment, the patient is randomised to either bCBT or TAU. Patients are informed about the randomisation outcome by the researchers via telephone and therapists via e-mail. Treatment starts as soon as possible after the inclusion, preferably within two weeks. Participants will be informed that they can withdraw from the study at any time, without any statement of reasons and without any consequences for their subsequent treatment.

Patients who are not eligible to participate will be notified and remitted to regular treatment trajectories within the participating mental healthcare centres.

Randomisation and blinding {#Sec7}
--------------------------

Randomisation will take place at an individual level stratified by mental healthcare centre. The allocation will be conducted centrally at the VU Amsterdam by an independent team of researchers which is not involved in the trial. A computerised random number generator \[[@CR39]\] is used to produce the allocation scheme with an allocation ratio 1:1. Subjects will be randomised into two groups: bCBT or TAU. The allocation is concealed, researchers and clinicians will be unknown to the randomisation scheme. Blinding for the treatment is not possible as it will be clear to both therapists and patients when the treatment is blended or not. However, the assessor conducting the M.I.N.I. at follow-up will be blinded to treatment status. The flowchart of the study is presented in Fig. [1](#Fig1){ref-type="fig"}, according to CONSORT guidelines \[[@CR40]\].Fig. 1Study flowchart

Blended intervention {#Sec8}
--------------------

The treatment manual is based on evidence-based Cognitive Behavioural Therapy (CBT) protocols implemented in routine practice \[[@CR41]\] and recommendations in treatment guidelines for depression \[[@CR42], [@CR43]\]. The blended model provides CBT by integrating individual face-to-face (FTF) sessions and online sessions, supported by a smartphone application for the real-time monitoring of patients' state in their natural environment (ecological momentary assessment: EMA). Through the mobile phone application, patients will also get automated motivational messages stimulating engagement on the platform as well as reminders to encourage treatment-related activities and improve compliance (ecological momentary intervention: EMI).

Patients receive ten FTF and nine online sessions over a period of 19--20 weeks, adhering to the usual time frame for the face-to-face CBT. The FTF and online sessions are weekly alternated (ratio 50/50). Communication between therapist and patient in-between the FTF sessions is asynchronous. The online part of the blended intervention is called "Moodbuster" \[[@CR44]\].

Online treatment platform {#Sec9}
-------------------------

Moodbuster is based on the ICT4Depression platform (ICT4D), developed in a previous European FP7 project and applied in three small-scale clinical feasibility pilot trials \[[@CR29], [@CR45]\]. ICT4D was originally developed as a self-help system and is for the current project adapted to fit the blended format where therapist support is included. Previous to the proposed trial, a technical pilot of Moodbuster was conducted to ensure good system stability, responsiveness, functionality and usability in live trials. The ICT-platform Moodbuster is currently available in five languages: English, Dutch, German, Polish and French.

The platform consists of 1) a *patient portal*: an online treatment environment for patients, with access to the treatment modules, homework exercises, mood graph, calendar and messaging system, 2) *a therapist portal*: a back-office for caregivers to monitor their patients and provide written feedback on exercises and progress in a secure way, and 3) a *mobile application* for real-time monitoring of mood state, cognitions, activities, social interaction, and sleep of the patient, as well as providing automated tailored reminders and motivational messages. Patients and therapists access the platform with a personalised log-in. Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} show screenshots of the Moodbuster platform.Fig. 2Moodbuster website: homepage of the patient portalFig. 3Moodbuster website: patient profile on therapist portal

Blended treatment protocol {#Sec10}
--------------------------

Moodbuster contains an introduction module and six online treatment modules that are applied as integrated components of the FTF sessions within the blended treatment protocol. All treatment modules have the same structure, starting with an introduction and video about the content and purpose of the module, followed by didactical parts and exercises to apply the learned theory to own situations, and ending with a questionnaire assessing symptom severity and evaluation of the module. Patients work on one module at a time and get gradual access to the modules. The introductions of the modules are accessible at all time, but before entering a new module the patient has to confirm that the choice to activate that module was made in accordance with the therapist.

The blended treatment starts with the *Introduction* and *Psycho-education* module and ends with *Relapse prevention*. The order of the intermediate modules -- *Cognitive restructuring, Behavioural activation*, *Problem solving skills* and *Physical exercise* -- may vary, depending on the needs and preferences of the patient. The modules *Cognitive restructuring* and *Behavioural activation* are obligatory, as being part of the core components of the treatment. Therapists are required to include all four elements of CBT (psycho-education, cognitive restructuring, behavioural activation and relapse prevention), but are free to decide how many sessions are spent on each module. On completion of treatment, patients can continue to access Moodbuster to reread information and look up or repeat homework exercises.

Guidelines for the 45 min *FTF sessions* are to monitor and discuss depression symptoms based on mood ratings on the mobile phone, to review patients experiences with the homework exercises and the given feedback and to explain rationale and exercises within the current or upcoming module. The FTF sessions follow up on the CBT modules where content and exercises can be discussed in more depth, but also gives the therapist the opportunity to respond to the individual patient's needs. Within the *online sessions* the patient works through a module and completes homework exercises. The therapist provides the patient with personalised written feedback on progress and content of exercises they have completed on the online treatment platform. The feedback is given at a scheduled time in-between the FTF sessions, via the Moodbuster messaging system. Providing online feedback will take therapists approximately 15 min. The *mobile phone application* will be used for EMA: the real-time monitoring of patients state in their natural environment. Patients will be prompted to rate their mood state, cognitions, activities, social interaction and sleep on a scale from 0--10 (from low to high). The EMA assessment questions and schedule are presented in Table [1](#Tab1){ref-type="table"}. On the mobile application, patients will also receive automated motivational text messages to keep engaged with Moodbuster (rate mood and log in on platform), as well as reminders for scheduled activities within the modules and appointments with their therapist (EMI).Table 1EMA assessment questions and scheduleTimingConceptQuestionFull EMA diaryMorning diarySleepHow well did you sleep last night?MoodHow is your mood right now?WorryingHow much do you worry at the moment?Self-esteemHow do you feel about yourself right nowEvening diaryMoodHow is your mood right now?WorryingHow much do you worry at the moment?Self-esteemHow do you feel about yourself right nowEnjoy activitiesHow much did you enjoy activities today?Social contactsHow much were you involved in social interactions today?Pleasant activity levelTo what extent did you accomplish pleasant activities today?Mood ratingRandomMoodHow is your mood right now?

Therapists {#Sec11}
----------

Either licenced CBT therapists or CBT therapists in training who work under supervision of an experienced CBT therapist will provide the blended depression treatment. All will receive extensive training on how to deliver the treatment (use of platform, skills for written feedback, blended protocol). To ensure treatment fidelity (1) a detailed treatment manual is available to guide therapists through the treatment, (2) regular supervision is provided between the therapists and the research coordinator and/or CBT supervisor and (3) therapists will fill in fidelity questionnaires after each session registering the (module) interventions used and the length of the contact. The number and frequency of sessions will be derived from the Electronic Patient Record Form and therapists' activities on the platform will be assessed through track and change functionalities (log files).

Treatment as usual {#Sec12}
------------------

TAU is defined as the routine care that subjects receive when they are treated for depression in routine specialised outpatient mental healthcare. The type of treatment can vary and may consist of face-to-face psychotherapy (mainly CBT, interpersonal psychotherapy (IPT) or supportive therapy), antidepressant medication, running therapy, or a combination of these. We will not interfere with TAU but we will monitor carefully treatment utilisation through patient records, self-reported healthcare utilisation and fidelity checklist from therapists (see assessments). In both arms patients may receive medication; in this sense usual care is being followed.

Assessments {#Sec13}
-----------

Measures will be taken at baseline and at 3, 6 and 12 months after baseline. The diagnostic interview (M.I.N.I.) at baseline will be conducted by telephone by trained interviewers. At 12 months follow-up the depression, anxiety and PTSD sections of the M.I.N.I. will be assessed again by telephone by an interviewer blinded to treatment allocation. All other assessments will be performed online via a link to the self-report questionnaires sent by e-mail. Table [2](#Tab2){ref-type="table"} provides an overview of the measures and their time of assessment.Table 2Overview of measuresVariableInstrumentT0^\*^T1^\*^T2^\*^T3^\*^*Measures taken from patient*Demographics (patient characteristics)XCurrent and history of treatmentXDiagnosis of depression and comorbid disordersM.I.N.I. 5.0XXDepressive symptomsPHQ-9XXXXDepressive symptoms & severityQIDS-SR-16XXXXHealth related well-being (QALY)EQ-5D-5LXXXXHealth care uptake and productivity losses TIC-PTIC-PXXXXSense of masterySOMSXXXXTreatment preferenceXPatient expectancyCEQXTherapeutic allianceWAI-SF-PTXTechnology allianceWAI-Online Therapy^a^XClient satisfaction with treatmentCSQ-8XSatisfaction with the online program SUSSUS^a^XPossible negative side-effectsINEPX*Measures taken from therapist*Therapeutic allianceWAI-SF-TH^b^XSatisfaction with the online programSUS^c^X^a^Offered to condition receiving blended treatment only^b^Has to be completed for each patient. Offered at the same time point as T1 assessment of the patient^c^Has to be completed once per therapist after completion of the first blended treatment\*T0 refers to baseline and T1, T2 and T3 to the 3, 6 and 12 month questionnaires

Outcome measures {#Sec14}
----------------

### Primary outcome measure {#Sec15}

The primary outcome measure is *symptoms of depression* as assessed with the Patient Health Questionnaire-9 (PHQ-9) \[[@CR46]\]. The PHQ-9 is a nine-item mood module that can be used to screen and to diagnose patients with depressive disorders. The 9 items are each scored on a 0--3 scale, with the total score ranging from 0--27 and higher scores indicating more severe depression. The PHQ-9 has shown to have good psychometric properties \[[@CR47], [@CR48]\].

The Quick Inventory of Depressive Symptomatology Self-Report (QIDS-16-SR) is used in addition to the PHQ-9, because this measure is more often used (especially in specialised mental healthcare) and therefore makes better comparison with other studies possible. The QIDS assesses *depression severity* and consists of 16 items (each item scores 0--3, total range 0--48), with higher total scores being indicative of a higher severity of depressive symptoms. The QIDS includes symptom domains of MDD based on DSM-IV and Research Diagnostic Criteria (RDC). The QIDS has shown highly acceptable psychometric properties, with internal consistency of α = .86 \[[@CR49]\]. The cut-off points of 6, 11, 16 and 21 represent the thresholds for mild, moderate, severe and very severe depression, respectively.

### Secondary outcome measures {#Sec16}

*A diagnosis of depression* will be assessed with section A and B of the *MINI International Neuropsychiatric Interview* (M.I.N.I.) version 5.0, a structured diagnostic interview based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and on International Classification of Diseases (ICD-10) criteria \[[@CR37]\]. In comparison with the patient-rated version of the SCID, the M.I.N.I. achieved a good Kappa score of 0.84 with a sensitivity of 0.96 and a specificity of 0.88 in diagnosing Major Depressive Disorder (MDD) \[[@CR50]\].

The full M.I.N.I., with exception of section M (Anorexia Nervosa), N (Bulimia nervosa), and P (Antisocial personality disorder), will be conducted at baseline (T0) to determine lifetime and current depression, as well as current comorbid psychiatric. At 12 month follow-up (T3), the depression, anxiety and PTSD sections of the M.I.N.I. will be assessed again, covering the past 12 months.

*Demographic variables* including age, sex, ethnicity, marital status, educational level and employment status, as well as *history of treatment* for mental health problems will be assessed at baseline. In addition, patients will be asked about *treatment preference*, indicating which treatment alternative they prefer (bCBT or TAU) before being allocated to one of the two conditions.

*Patients' expectancy of treatment* will be assessed after randomisation with the Credibility and Expectancy Questionnaire (CEQ). This questionnaire consists of six items measuring expectancies toward the therapy and the credibility of treatment options. The items are scored on one of two scales, one 9-point Likert scale ranging from 0 (not at all) to 9 (absolutely) or a continuous scale ranging from 0 % (not at all) to 100 % (absolutely). The sum score on credibility and expectancy can vary between 3 and 27, with higher scores being indicative of more positive attitudes. Both factors (credibility and expectancy) have shown to be stable across different populations, with high internal consistency within each factor \[[@CR51]\].

*Locus of control* will be assessed with the 5-item version of the Sense of Mastery Scale \[[@CR52]\], with proven good reliability \[[@CR53]\]. Questions are scored on a Likert-scale ranging from 1 ('totally disagree') to 5 ('totally agree'). The total score ranges from 5 to 25, with higher scores being indicative of a higher degree of perceived control. The Sense of Mastery Scale will be administered at all time points (T0-T3) to assess changes in locus of control.

*Patient's satisfaction with the treatment* will be assessed with Client Satisfaction Questionnaire (CSQ-8), used to measure global patient satisfaction \[[@CR54]\]. The questionnaire consists of 8 items that are measures on a 4-points scale. Total scores range from 8 to 32, with higher scores being indicative of higher levels of satisfaction. The CSQ-8 has high internal consistency of α = .93 \[[@CR55]\].

*Satisfaction with the online platform* will be evaluated with the System Usability Scale (SUS), a simple 10-item questionnaire giving a global view of subjective assessments of usability of a technology system \[[@CR56]\]. All items are measured on a 5-point Likert scale ranging from 'strongly disagree' to 'strongly agree'. Total SUS scores have a range from 0--100. The questionnaire was found to be reliable and robust \[[@CR57]\]. The SUS has to be completed by patients receiving bCBT only, and once per therapist three months after starting with their first blended treatment.

The *therapeutic alliance* between therapists and patient will be assessed with the short version of the Working Alliance Inventory (WAI-SF) \[[@CR58]\], Dutch version \[[@CR59]\]. The WAI-SF is a 12-item self-report questionnaire with responses on a 5-point Likert scale ranging from'never or rarely' to 'very often'. The questionnaire covers three dimensions of working alliance: 1) therapeutic goals, 2) tasks, and 3) bond. The subscales have shown to have good internal consistencies (α \> .80). Both the patient and the therapist version of the questionnaire will be administered at T1, to determine the quality of the therapeutic alliance.

The *alliance between the patient and technologies* will be assessed with an adapted version of the WAI: the Working Alliance Inventory -- Online Therapy, developed by Labpsitec (Labority of Psychology and Technology). The items address goals and tasks agreement with the online treatment program, and not with the therapist.

To assess possible *negative side-effects of the treatment*, the Inventory of Negative Effects of Psychotherapy (INEP) \[[@CR60]\] will be administered at T2 (6 months after baseline). The version used in this study consists of 15 items, assessing a range of common changes participants experienced in line with their therapy, concerning their social and work environment. The following domains are covered: negative interpersonal changes, negative effects in an intimate relationship, family/friends, perceived dependence from therapist, stigmatisation. All items are rated on a 4-point Likert scale. For each item, respondents also state whether they attribute the adverse effects on the therapy or on other circumstances. Only item scores of those negative effects that were attributed on the therapy are added to the total score. Higher total scores indicate more negative effects. The INEP shows an internal consistency of α = 0.85 \[[@CR60]\]. For the use in this study, the questionnaire was translated by the forwards-backwards method, i.e. the questionnaire was first translated from English into Dutch by two persons who reached consensus by discussion. Next, the questionnaire was translated back to English and was compared with the original questionnaire.

### Economic evaluation {#Sec17}

*Quality of life* will be determined with the five-level version of the EuroQol (EQ-5D-5L), a self-report questionnaire assessing the health related well-being of participants \[[@CR61]\]. The questionnaire consists of five items: mobility, self-care, daily activities, discomfort and mood state. Each item has five response categories ranging from 'no problems' to 'a lot of problems' \[[@CR62]\]. Furthermore, this scale contains a visual analogue scale concerning health state. The EQ-5D-5L health states will be converted to utility scores using the Dutch tariff. Quality-adjusted life-years (QALYs) will be calculated by multiplying the utility of a specific health state by the time spent in that health state. Changes in health states between measurements will be linearly interpolated. The EQ-5D-5L holds acceptable levels of content validity \[[@CR63]\] and has demonstrated valid redistribution, reduced ceiling, and improved discriminatory power and convergent validity compared to the EQ-5D-3L \[[@CR64]\].

*Health care utilisation* and *productivity losses due to illness* will be measured using an adapted version of the Trimbos and iMTA Questionnaires on Costs Associated with Psychiatric Illness (TiC-P), a self-report questionnaire consisting of two different parts that can be administrated separately \[[@CR65]\]. Part I will be used to assess the participants' healthcare utilisation and medication use. Part II (short form Health and Labor Questionnaire; SF-HLQ) consists of 11 items measuring lost productivity costs resulting from absenteeism (being absent from work because of illness) and presenteeism (being present at work while ill which may lead to reduced efficiency).

### Engagement and usage measures for bCBT {#Sec18}

Activities on the platform such as number of visits, time in-between logins and number of messages exchanged between patient and therapist, will be assessed through track and change functionalities (log files). Data on how patients use online modules (frequency, duration, order, completion), how they rate them and to what extent they adhere, will also be obtained through usage statistics on the Moodbuster online treatment platform.

Patients receiving the blended treatment will as part of the treatment protocol additionally fill out the PHQ-8 at the end of each module, for monitoring treatment outcome (i.e., all items on the PHQ-9 scale except the ninth item). As this data is being gathered in a self-administered fashion and direct action on positive responses on the ninth item inquiring "thoughts that you would be better off dead or of hurting yourself in some way" is not feasible, it was chosen to exclude this item. Patients are instructed to use existing services of the mental health care organisations when they feel the need to contact a doctor or a therapist outside working hours. The PHQ-8 has similar operating characteristics as the PHQ-9 (sensitivity, specificity, and positive predictive value), regardless of the threshold \[[@CR38]\].

Sample size {#Sec19}
-----------

For the European study as a whole, the sample size calculation is based on the non-inferiority design and calculated for the primary clinical outcome symptoms of depression. The non-inferiority margin was set at ∆Cohen's d = 0.20, which is a conservative estimate of the subjective minimal important difference that is noticeable by patients \[[@CR66]\]. To determine that there is no difference between blended depression treatment and TAU on the primary clinical outcome, a total of 1052 patients is required to be 90 % certain (power of .90) that the lower limit of the two sided 95 % confidence interval will be above the non-inferiority limit of Cohen's *d* = -0.2. To allow for expected drop-out and variation between settings, the total number of participants to be recruited will be 1200.

For the current trial in the Netherlands we aim to include 156 participants (78 per arm). This sample size will be sufficient to be 80 % sure (i.e. power = 1-ß = 0.80) that the lower limit of a one-sided 95 % confidence interval (or equivalently a 90 % two-sided confidence interval) will be above a non-inferiority limit of -0.4 if we assume that there is no difference between the standard and blended depression treatment. A margin of 0.4 was judged acceptable, as this range of small to moderate difference in effect size will not result in clinically important differences \[[@CR67]\].

Planned statistical analyses {#Sec20}
----------------------------

In a non-inferiority trial, the study objective should be achieved in both the intention to treat and per-protocol population \[[@CR68]\]. Analysis will be based on intention to treat (ITT) design, including all participants randomised in the study. Participants will be encouraged to provide assessment data, regardless of treatment adherence. Additionally, per-protocol (PP) analysis will be conducted, including only participants who followed the treatment protocol of the assigned treatment. Non-inferiority should be demonstrated also in the PP analysis, because ITT tends to dilute differences \[[@CR69]\]. All analyses will be performed using the Statistical Package for the Social Sciences (SPSS), version 20.0.

### Economic evaluation {#Sec21}

We will perform an economic evaluation from societal perspective, conducting a cost-effectiveness analysis (CEA) and cost-utility analysis (CUA). The CEA will be based on treatment response, defined as a 50 % pre-post reduction of QIDS-SR depressive symptoms \[[@CR49]\]. The CUA will be conducted using quality adjusted life years (QALYs) as a generic measure of health gains. Multiple imputation using chained equations (MICE) will be used to impute missing cost and effect data. Predictive Mean Matching will be used to account for the skewed distribution of costs \[[@CR70]\]. Variables that will be included in the multiple imputation model are variables related to missingness, variables related to costs and effects at 12 months of follow-up and all variables included in the analysis model. The number of imputations will be increased until the fraction of missing information (FMI) is 5 % or less \[[@CR70]\]. The completed datasets will be analysed separately and pooled using Rubin's rules \[[@CR71]\].

Multilevel analyses with adjustment for mental health care institution will be done to estimate differences in costs and effects between bCBT and TAU while correcting for potential effect modifiers and confounders. Incremental cost-effectiveness ratios (ICERs) will be calculated by dividing the difference in costs by the difference in effects. Bias-corrected and accelerated bootstrapping with 5000 replications will be used to estimate statistical uncertainty. Bootstrapped cost-effect pairs will be plotted on cost-effectiveness planes (CE planes) to visualize the uncertainty surrounding the ICERs. Moreover, for decision-making purposes cost-effectiveness acceptability curves will be estimated showing the probability that bCBT is cost-effective in comparison with TAU at a range of different ceiling ratios. Finally, to test the robustness of our findings, sensitivity analyses will be performed. First, the economic evaluation will be conducted from a healthcare perspective. Secondly, a per protocol analysis will be done in which only participants completing the bCBT treatment protocol will be included.

### Clinical evaluation {#Sec22}

Independent *t*-tests and *χ*2-tests will be used to estimate between-group differences in demographics and pre-treatment measures at baseline. Outcomes on continuous outcome variables at T1, T2 and T3 will be analysed via mixed-model analyses, with participants as random effects, and time (T1-T3), group (bCBT vs. TAU) and time x group as fixed effects, with baseline scores as a single covariate. To assess the magnitude of treatment effects, Cohen's *d* effect sizes \[[@CR72]\] for each time point will be calculated by dividing MM parameter estimates of fixed effects at each post-treatment assessment by the pooled standard deviation of baseline scores. Effect sizes under 0.2 are deemed to be small, 0.5 to be moderate and 0.8 to be large \[[@CR72]\].

Differences in response and remission rates, as well as adherence rates will be examined using *t*-tests and *χ*2-tests. In addition, moderator analysis will be conducted for demographic variables such as gender, age, educational level, partner status, employment status, as well as treatment and patient characteristics.

Discussion {#Sec23}
==========

The aim of this study is to evaluate the clinical and cost-effectiveness of blended CBT where face-to-face treatment is combined with internet and mobile technologies, as compared to treatment as usual for adults with MDD in routine specialised mental healthcare. Keeping depression treatment accessible, feasible and affordable is of high importance, considering the large individual and economic burden of this disease \[[@CR1], [@CR2]\]. The study described in this paper is the trial conducted in the Netherlands as part of E-COMPARED. The results of this study will provide insight into the health-economical outcomes of blended treatment and give an indication in the value of implementing blended treatment into routine specialised mental healthcare.

Although previous findings have shown similar effect of guided iCBT compared to traditional FTF treatment \[[@CR17], [@CR19]\], the current study will give an answer to the question whether this also holds for bCBT in more complex and severely depressed patients in specialised care, as well as whether bCBT is more cost-effective than regular depression treatments. Given that the number of required FTF sessions is reduced by replacing them with online sessions, it is assumed that bCBT might lead to cost savings. At the same time, waiting lists could be diminished as therapists can treat more patients in a given time period. The quicker treatment can start, the sooner people suffering from depression do recover and the sooner they are able to participate in society. Down the road, this could have a positive impact on the social economic consequences of depression seen that productivity losses due to the illness (absenteeism and presenteeism) is often the biggest expense \[[@CR73], [@CR74]\].

A major strength of the present study, is that it is one of the first to assess blended treatment instead of internet-based interventions used as standalone or add-ons, in the treatment of depression in routine practice. The assumption underlying the integrated approach within blended treatment, is that the benefits of online treatment are combined with the advantages of FTF therapy. However, many questions regarding a blended treatment format are still unanswered, e.g. on how to best blend the two modes of delivery, on program structure and flexibility or on frequency and content of therapist support \[[@CR24], [@CR25]\]. This study will contribute in yielding meaningful answers to these questions. It will also become clear to what extent the blended intervention suits patients in specialised mental healthcare, by looking at adherence, dropout and satisfaction with treatment.

Another strength is the innovative character: the blended treatment in our study also includes a mobile component, making ecological momentary assessment and intervention techniques possible. The real-time monitoring of patient's state can enhance insight into meaningful patterns of the depression, aspects contributing to changes in mood and influence of treatment interventions, acting as an intervention itself. With EMI, treatment engagement and completion of therapy-related homework tasks can also actively be encouraged, for example by sending reminders for scheduled activities. Adding these new possibilities, can aid in personalizing treatment and optimizing adherence \[[@CR27], [@CR75]\].

A further strong feature of this trial is that patients with comorbidity will only be excluded when alternative treatment for that comorbid condition is required primary to the treatment of MDD, similar to usual procedures in the treatment indication for depression. This will maximize the external validity of the trial and reflect the heterogeneity and complexity of the patient population in specialised routine mental healthcare settings. Also, we will not interfere with current practice within the TAU group. By following the usual care paths for depression, generalizability to routine practice is strengthened. This strength can also be regarded as a limitation, as TAU cannot be foreknown and is expected to be heterogeneous. However, this study is designed to be a pragmatic trial and it is our aim to compare the effectiveness of bCBT with current usual care. TAU will be monitored carefully, to control for potential confounding effects.

The current study also presents us the challenge of providing a new treatment modality within everyday practice. To aid the implementation and ensure treatment fidelity, therapists receive extensive training on how to deliver bCBT, (technical) support is offered by the research team and therapists are provided with a treatment manual. Taking into account the heterogeneity of the disorder, our blended protocol allows for some flexibility, e.g. in the order of the modules and time spent on each module. By keeping track of activities on the Moodbuster platform, we will be able to get insight into what happens during therapy to increase knowledge on the suitability and applicability of blended depression treatment for patients in specialised clinical practice.

Overall, this study will provide mental healthcare stakeholders evidence-based information on the clinical and cost-effectiveness of bCBT and recommendations on how bCBT can be integrated into routine specialised mental healthcare settings.

Trial status {#Sec24}
------------

The trial is in the on-going recruitment phase. Recruitment started in July 2015.

Ethics {#Sec25}
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The protocol for this study has been approved by the Medical Ethics Committee of the VU University Medical Centre (registration number 2015.078). The study is being conducted in Compliance with the Declaration of Helsinki \[[@CR76]\]. Informed signed consent to participate in the study will be obtained from all participants.
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